Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.

ABSTRACT:

Introduction

In 2018, durvalumab was approved by the U.S. Food and Drug Administration as consolidation immunotherapy for patients with stage III NSCLC after definitive chemoradiotherapy (CRT). However, whether durvalumab benefits patients with EGFR-mutated NSCLC remains unknown.

Methods

We conducted a multi-institutional retrospective analysis of patients with unresectable stage III EGFR-mutated NSCLC who completed concurrent CRT. Kaplan-Meier analyses evaluated progression-free survival (PFS) between patients who completed CRT with or without durvalumab.

Results

Among 37 patients, 13 initiated durvalumab a median of 20 days after CRT completion. Two patients completed 12 months of treatment, with five patients discontinuing durvalumab owing to progression and five o

SUBMITTER: Aredo JV 

PROVIDER: S-EPMC12665271 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature